Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)

Detalhes bibliográficos
Ano de defesa: 2020
Autor(a) principal: Maranhão, Sarah Sant'Anna
Orientador(a): Pessoa, Claudia do Ó
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Não Informado pela instituição
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://www.repositorio.ufc.br/handle/riufc/53367
Resumo: Acute myeloid leukemia (AML) is the malignant hematologic disease most common in adults characterized by clonal proliferation of immature myeloid cells in the peripheral blood, bone marrow and other tissues. Treatment for AML has been less than optimal with little changes in the standard induction regimen (anthracycline and cytarabine) over the past 40 years. AML treatment landscape has been changing with new therapies emerging in recent years, however such progress remains unsatisfactory with a low survival rate. Therefore, the constant search for new therapies or drug combinations that can assist AML treatment. In this thesis, we present two new approaches to treat AML. The first consists of a small synthetic quinoxaline synthesized in Brazil. In previous studies, PJOV56 showed an antineoplastic potential by inducing autophagy in colorectal cancer cells (HCT-116). In the present study, PJOV56 exhibited better cytotoxic activity in AML cell lines, inducing DNA damage in KG1 cells. The activation of DNA damage response pathways included phosphorylation of H2AX, CHK1 and CHK2 with consequent cell cycle arrest in G0/G1 and S phases, triggering apoptotic process. PJOV56 also showed safety with reduced genotoxicity in healthy cells (inducing micronucleus formation and DNA damage only at concentrations thirty times higher than the tumor cells IC50 values). In addition, the molecule did not induced toxicity in C57BL/6 healthy mice. The second treatment proposed consists of a combination therapy between and RNA Pol I inihibitor (CX- 5461) and an CDKs inhibitor (Dinaciclib). Combination therapy, previously tested in a syngeneic AML mouse model that predicts human response MLL/ENL Nras p53WT, led to a survival benefit indicative of a synergistic effect. Here the molecular mechanism underlying this phenomenon was evidenced in vivo by drugs target inhibition, triggering of apoptotic process with capase 3 and PARP cleavage and phosphatidylserine externalization and cell cycle arrest. Along with the combination therapeutic efficacy was proven in another AML mouse model beyond a MLL rearrangement, AML1/ETO9 Nras p53WT. Thus, this thesis suggests two new therapeutic approaches to potentially treat AML.
id UFC-7_c67d2831eef39a2c84d34d9b1e0576a4
oai_identifier_str oai:repositorio.ufc.br:riufc/53367
network_acronym_str UFC-7
network_name_str Repositório Institucional da Universidade Federal do Ceará (UFC)
repository_id_str
spelling Maranhão, Sarah Sant'AnnaPessoa, Claudia do Ó2020-08-07T21:18:29Z2020-08-07T21:18:29Z2020-07-08MARANHÃO, S. S. Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA; e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib). 2020. 18 f. Tese (Doutorado em Farmacologia) – Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2020.http://www.repositorio.ufc.br/handle/riufc/53367Acute myeloid leukemia (AML) is the malignant hematologic disease most common in adults characterized by clonal proliferation of immature myeloid cells in the peripheral blood, bone marrow and other tissues. Treatment for AML has been less than optimal with little changes in the standard induction regimen (anthracycline and cytarabine) over the past 40 years. AML treatment landscape has been changing with new therapies emerging in recent years, however such progress remains unsatisfactory with a low survival rate. Therefore, the constant search for new therapies or drug combinations that can assist AML treatment. In this thesis, we present two new approaches to treat AML. The first consists of a small synthetic quinoxaline synthesized in Brazil. In previous studies, PJOV56 showed an antineoplastic potential by inducing autophagy in colorectal cancer cells (HCT-116). In the present study, PJOV56 exhibited better cytotoxic activity in AML cell lines, inducing DNA damage in KG1 cells. The activation of DNA damage response pathways included phosphorylation of H2AX, CHK1 and CHK2 with consequent cell cycle arrest in G0/G1 and S phases, triggering apoptotic process. PJOV56 also showed safety with reduced genotoxicity in healthy cells (inducing micronucleus formation and DNA damage only at concentrations thirty times higher than the tumor cells IC50 values). In addition, the molecule did not induced toxicity in C57BL/6 healthy mice. The second treatment proposed consists of a combination therapy between and RNA Pol I inihibitor (CX- 5461) and an CDKs inhibitor (Dinaciclib). Combination therapy, previously tested in a syngeneic AML mouse model that predicts human response MLL/ENL Nras p53WT, led to a survival benefit indicative of a synergistic effect. Here the molecular mechanism underlying this phenomenon was evidenced in vivo by drugs target inhibition, triggering of apoptotic process with capase 3 and PARP cleavage and phosphatidylserine externalization and cell cycle arrest. Along with the combination therapeutic efficacy was proven in another AML mouse model beyond a MLL rearrangement, AML1/ETO9 Nras p53WT. Thus, this thesis suggests two new therapeutic approaches to potentially treat AML.A leucemia mieloide aguda (LMA) é a doença hematológica de medula óssea mais comum em adultos. O tratamento da LMA tem sido pouco satisfatório, havendo poucas mudanças no regime padrão (citarabina e antraciclinas) de tratamento nos últimos anos; apesar do surgimento de novas terapias, que permanecem pouco adequadas, com uma taxa de sobrevivência ainda baixa. Haja vista tal conjectura, objetivou-se com a presente tese buscar duas novas possibilidades terapêuticas para a LMA. A primeira consiste em uma molécula sintética (PJOV56), pertencente à classe das quinoxalinas que, em estudos anteriores, demonstrou o seu potencial anticâncer induzindo autofagia em células de câncer colorretal (HCT-116). Neste estudo, o potencial antitumoral da PJOV56 foi avaliado contra células leucêmicas. A molécula demonstrou ser mais ativa contra células de LMA, induzindo dano de DNA em células KG1, desencadeando a ativação de componentes cruciais das vias de resposta ao dano de DNA, como as proteínas H2AX, CHK1 e CHK2, com consequente parada de ciclo celular nas fases G0/G1 ou S e desencadeamento do processo apoptótico. A PJOV56 exibiu-se como uma molécula segura com poder genotóxico reduzido em células não tumorais, avaliado pela formação de micronúcleo e dano de DNA apenas em concentrações 30 vezes superiores aos valores de IC50 em células tumorais. Além disso, não induziu toxicidade em animais saudáveis C57BL/6 após doses escalonadas de 35mg/Kg. A segunda forma de tratamento proposta consiste em uma combinação terapêutica entre um inibidor de RNA Pol I (CX-5461) e um inibidor de CDKs (C) que, em estudos anteriores, demonstraram eficácia terapêutica com aumento da sobrevivência sobre as monoterapias em modelos animais singênicos de LMA. Comprovou-se, portanto, neste estudo, o mecanismo pelo qual essa combinação atua in vivo através de análises em células da medula óssea e baço em diferentes tempos de tratamento, utilizando dois modelos murinos de LMA MLL/ENL e AML1/ETO9 Nras p53WT. Os resultados confirmaram a inibição dos alvos específicos RNA Pol I e CDK9 com redução da carga tumoral e desencadeamento do processo apoptótico, comprovado por clivagem da caspase 3 e PARP, externalização da fosfatidilserina e parada do ciclo celular. Desse modo, foi possível validar duas novas terapias com potencial para o tratamento da LMA em modelos pré-clínicos.Leucemia Mieloide AgudaQuinoxalinasNovas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)New therapeutic strategies for the treatment of acute myeloid leukemia (AML): PJOV56, a DNA damage agent and a combination of polymerase I (CX-5461) and CDK (Dinaciclib) inhibitorsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisporreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccessLICENSElicense.txtlicense.txttext/plain; charset=utf-81978http://repositorio.ufc.br/bitstream/riufc/53367/2/license.txt4247602db8c5bb0eb5b2dc93ccdf9494MD52ORIGINAL2020_tese_ssmaranhao.pdf2020_tese_ssmaranhao.pdfapplication/pdf161410http://repositorio.ufc.br/bitstream/riufc/53367/3/2020_tese_ssmaranhao.pdfb778f506aa60f8b5ccb532ec256c4a27MD53riufc/533672020-08-07 18:19:42.64oai:repositorio.ufc.br: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Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2020-08-07T21:19:42Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false
dc.title.pt_BR.fl_str_mv Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
dc.title.en.pt_BR.fl_str_mv New therapeutic strategies for the treatment of acute myeloid leukemia (AML): PJOV56, a DNA damage agent and a combination of polymerase I (CX-5461) and CDK (Dinaciclib) inhibitors
title Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
spellingShingle Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
Maranhão, Sarah Sant'Anna
Leucemia Mieloide Aguda
Quinoxalinas
title_short Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
title_full Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
title_fullStr Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
title_full_unstemmed Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
title_sort Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib)
author Maranhão, Sarah Sant'Anna
author_facet Maranhão, Sarah Sant'Anna
author_role author
dc.contributor.author.fl_str_mv Maranhão, Sarah Sant'Anna
dc.contributor.advisor1.fl_str_mv Pessoa, Claudia do Ó
contributor_str_mv Pessoa, Claudia do Ó
dc.subject.por.fl_str_mv Leucemia Mieloide Aguda
Quinoxalinas
topic Leucemia Mieloide Aguda
Quinoxalinas
description Acute myeloid leukemia (AML) is the malignant hematologic disease most common in adults characterized by clonal proliferation of immature myeloid cells in the peripheral blood, bone marrow and other tissues. Treatment for AML has been less than optimal with little changes in the standard induction regimen (anthracycline and cytarabine) over the past 40 years. AML treatment landscape has been changing with new therapies emerging in recent years, however such progress remains unsatisfactory with a low survival rate. Therefore, the constant search for new therapies or drug combinations that can assist AML treatment. In this thesis, we present two new approaches to treat AML. The first consists of a small synthetic quinoxaline synthesized in Brazil. In previous studies, PJOV56 showed an antineoplastic potential by inducing autophagy in colorectal cancer cells (HCT-116). In the present study, PJOV56 exhibited better cytotoxic activity in AML cell lines, inducing DNA damage in KG1 cells. The activation of DNA damage response pathways included phosphorylation of H2AX, CHK1 and CHK2 with consequent cell cycle arrest in G0/G1 and S phases, triggering apoptotic process. PJOV56 also showed safety with reduced genotoxicity in healthy cells (inducing micronucleus formation and DNA damage only at concentrations thirty times higher than the tumor cells IC50 values). In addition, the molecule did not induced toxicity in C57BL/6 healthy mice. The second treatment proposed consists of a combination therapy between and RNA Pol I inihibitor (CX- 5461) and an CDKs inhibitor (Dinaciclib). Combination therapy, previously tested in a syngeneic AML mouse model that predicts human response MLL/ENL Nras p53WT, led to a survival benefit indicative of a synergistic effect. Here the molecular mechanism underlying this phenomenon was evidenced in vivo by drugs target inhibition, triggering of apoptotic process with capase 3 and PARP cleavage and phosphatidylserine externalization and cell cycle arrest. Along with the combination therapeutic efficacy was proven in another AML mouse model beyond a MLL rearrangement, AML1/ETO9 Nras p53WT. Thus, this thesis suggests two new therapeutic approaches to potentially treat AML.
publishDate 2020
dc.date.accessioned.fl_str_mv 2020-08-07T21:18:29Z
dc.date.available.fl_str_mv 2020-08-07T21:18:29Z
dc.date.issued.fl_str_mv 2020-07-08
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv MARANHÃO, S. S. Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA; e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib). 2020. 18 f. Tese (Doutorado em Farmacologia) – Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2020.
dc.identifier.uri.fl_str_mv http://www.repositorio.ufc.br/handle/riufc/53367
identifier_str_mv MARANHÃO, S. S. Novas estratégias terapêuticas para o tratamento da leucemia mieloide aguda (LMA): PJOV56, um agente causador de dano de DNA; e uma combinação terapêutica entre um inibidor de RNA Pol I (CX- 5461) e um inibidor de CDKs (Dinaciclib). 2020. 18 f. Tese (Doutorado em Farmacologia) – Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2020.
url http://www.repositorio.ufc.br/handle/riufc/53367
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Ceará (UFC)
instname:Universidade Federal do Ceará (UFC)
instacron:UFC
instname_str Universidade Federal do Ceará (UFC)
instacron_str UFC
institution UFC
reponame_str Repositório Institucional da Universidade Federal do Ceará (UFC)
collection Repositório Institucional da Universidade Federal do Ceará (UFC)
bitstream.url.fl_str_mv http://repositorio.ufc.br/bitstream/riufc/53367/2/license.txt
http://repositorio.ufc.br/bitstream/riufc/53367/3/2020_tese_ssmaranhao.pdf
bitstream.checksum.fl_str_mv 4247602db8c5bb0eb5b2dc93ccdf9494
b778f506aa60f8b5ccb532ec256c4a27
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)
repository.mail.fl_str_mv bu@ufc.br || repositorio@ufc.br
_version_ 1881776230524518400